[go: up one dir, main page]

MX2010006220A - Derivados de morfolina como agentes antiobesidad. - Google Patents

Derivados de morfolina como agentes antiobesidad.

Info

Publication number
MX2010006220A
MX2010006220A MX2010006220A MX2010006220A MX2010006220A MX 2010006220 A MX2010006220 A MX 2010006220A MX 2010006220 A MX2010006220 A MX 2010006220A MX 2010006220 A MX2010006220 A MX 2010006220A MX 2010006220 A MX2010006220 A MX 2010006220A
Authority
MX
Mexico
Prior art keywords
compounds
new compounds
preparation
dyslipidemias
diabetes
Prior art date
Application number
MX2010006220A
Other languages
English (en)
Inventor
Iain Simpson
Michael Higginbottom
Vien-Anh Anne-Nee-Nguyen Horgan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010006220A publication Critical patent/MX2010006220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos novedosos de la formula (I), a composiciones farmacéuticas que comprenden estos compuestos, a procesos para su preparación y el uso de estos compuestos como miméticas de modulador de receptor de leptina en la preparación de medicamentos para condiciones relacionadas con aumento de peso, diabetes de tipo 2 y dislipidemias.
MX2010006220A 2007-12-05 2008-12-05 Derivados de morfolina como agentes antiobesidad. MX2010006220A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0702699 2007-12-05
US2296608P 2008-01-23 2008-01-23
PCT/EP2008/066917 WO2009071678A2 (en) 2007-12-05 2008-12-05 Morpholine derivatives as antiobesity agents

Publications (1)

Publication Number Publication Date
MX2010006220A true MX2010006220A (es) 2010-08-17

Family

ID=40636684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006220A MX2010006220A (es) 2007-12-05 2008-12-05 Derivados de morfolina como agentes antiobesidad.

Country Status (10)

Country Link
US (1) US20090203695A1 (es)
EP (1) EP2240447A2 (es)
JP (1) JP2011506298A (es)
KR (1) KR20100097701A (es)
CN (1) CN102026976A (es)
AU (1) AU2008333111A1 (es)
CA (1) CA2715527A1 (es)
MX (1) MX2010006220A (es)
RU (1) RU2010126828A (es)
WO (1) WO2009071678A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2229362A1 (en) * 2007-12-05 2010-09-22 AstraZeneca AB Piperazines as anti-obesity agents
RU2010126842A (ru) * 2007-12-05 2012-01-10 Астразенека Аб (Se) Производные пиперазина и их применение в качестве модуляторов рецептора лептина
SG11201404508XA (en) * 2012-01-31 2014-10-30 Lilly Co Eli Novel morpholinyl derivatives useful as mogat-2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217866A (en) * 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
WO2001026641A2 (en) * 1999-10-13 2001-04-19 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
US20050215603A1 (en) * 2004-03-08 2005-09-29 Irini Akritopoulou-Zanze Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP2229362A1 (en) * 2007-12-05 2010-09-22 AstraZeneca AB Piperazines as anti-obesity agents
CN102026993A (zh) * 2007-12-05 2011-04-20 阿斯利康(瑞典)有限公司 新化合物iii
RU2010126842A (ru) * 2007-12-05 2012-01-10 Астразенека Аб (Se) Производные пиперазина и их применение в качестве модуляторов рецептора лептина

Also Published As

Publication number Publication date
WO2009071678A3 (en) 2009-07-23
EP2240447A2 (en) 2010-10-20
AU2008333111A1 (en) 2009-06-11
US20090203695A1 (en) 2009-08-13
JP2011506298A (ja) 2011-03-03
CN102026976A (zh) 2011-04-20
RU2010126828A (ru) 2012-01-10
CA2715527A1 (en) 2009-06-11
KR20100097701A (ko) 2010-09-03
WO2009071678A2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
MY149622A (en) Pyrazoles as 11-beta-hsd-1
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
IN2012DN01233A (es)
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MX2009010045A (es) Compuestos quimicos.
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
MX2010006259A (es) Piperazinas como agentes antiobesidad.
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
MX2009013501A (es) Compuestos piperidinicos y sus usos.
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MX2010001574A (es) Ligandos del receptor cannabinoide.
TW200738627A (en) Trialkylsilyl-indoles
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.
JO2770B1 (en) Organic compounds
MX2010006216A (es) Nuevos compuestos iii.
MX2010001243A (es) Composicion anti-inflamatoria.
CA2725949A1 (en) New pyridine derivatives as leptin receptor modulator mimetics
MX2010006220A (es) Derivados de morfolina como agentes antiobesidad.
TW200800993A (en) Organic compounds
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal